A detailed history of Keystone Financial Group transactions in Poseida Therapeutics, Inc. stock. As of the latest transaction made, Keystone Financial Group holds 15,000 shares of PSTX stock, worth $142,500. This represents 0.01% of its overall portfolio holdings.

Number of Shares
15,000
Previous 15,000 -0.0%
Holding current value
$142,500
Previous $43,000 2.33%
% of portfolio
0.01%
Previous 0.02%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 06, 2023

BUY
$1.62 - $2.79 $24,300 - $41,850
15,000 New
15,000 $35,000

Others Institutions Holding PSTX

About Poseida Therapeutics, Inc.


  • Ticker PSTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 85,775,600
  • Market Cap $815M
  • Description
  • Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant ...
More about PSTX
Track This Portfolio

Track Keystone Financial Group Portfolio

Follow Keystone Financial Group and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Keystone Financial Group, based on Form 13F filings with the SEC.

News

Stay updated on Keystone Financial Group with notifications on news.